Aarti Pharmalabs Announces Key Management Changes and Unaudited Q1 Results
Aarti Pharmalabs Limited has reported its unaudited financial results for the quarter ended June 30, 2026, alongside key corporate governance updates following a Board meeting held on August 7, 2026. The company also approved a capacity addition plan for its Development of Intermediate Block and reconstituted several board committees.Management Appointments and Corporate Governance Decisions
The Board of Directors considered and approved significant changes in leadership roles and the composition of key operational bodies. These decisions were made based on recommendations from the Nomination and Remuneration Committee, and are subject to shareholder approval at the Annual General Meeting.Key personnel changes include:
- Shri Rashesh C Gogri changing his role from Non-Executive Director to Managing Director with effect from October 1, 2026.
- Smt. Hetal Gogri Gala transitioning in her designation from Managing Director to Executive Director, effective October 1, 2026.
In addition to management changes, the Board also focused on strategic expansion and governance structure:
Capacity Expansion: The company approved a capacity addition for the Development of Intermediate Block at an estimated capital expenditure (capex) of Rs. 149 Crores. This project is financed through internal accruals and borrowings, with the goal of expanding capacity to serve intermediate and CDMO customers within one year.
Committee Reconstitution: The Board of Directors approved the reconstitution of three critical committees:
- Audit Committee: Members include Shri Bhavesh Vora (Chairman), Shri Vinay Nayak, Shri Vilas Gaikar, Smt. Jeenal Savla, Shri Narendra Salvi, and Shri Rashesh C Gogri.
- Corporate Social Responsibility (CSR) Committee: The committee is chaired by Smt. Hetal Gogri Gala and includes members Shri Pradeep Thakur, Smt. Jeenal Savla, and Shri Vilas Gaikar.
- Stakeholders Relationship Committee: This committee is chaired by Shri Parimal Desai and comprises Shri Narendra Salvi, Shri Bhavesh Vora, and Shri Rupal Vora.
Q1 Financial Performance Highlights
Aarti Pharmalabs Limited released its unaudited financial results for the quarter ended June 30, 2026. The company operates primarily in the Pharmaceuticals segment.Standalone Financial Results (Quarter Ended June 30, 2026)
The following table summarizes the standalone financials:
| Particulars | 30th June 2026 (Unaudited) | 31st March 2026 (Audited) | 30th June 2025 (Unaudited) | 31st March 2026 (Audited) |
|---|---|---|---|---|
| Revenue from Operations (Net) | 53,458.78 | 57,970.05 | 37,531.06 | 179,755.17 |
| Total Income | 53,751.91 | 59,023.06 | 37,608.19 | 181,287.50 |
| Total Expenses | 44,129.49 | 50,764.52 | 31,354.51 | 157,584.11 |
| Profit before Tax | 9,622.41 | 8,258.54 | 6,253.68 | 23,703.39 |
| Total Tax Expenses | 2,491.75 | 2,055.46 | 1,478.63 | 5,803.70 |
| Net Profit for the period | 7,130.66 | 6,203.07 | 4,775.05 | 17,620.20 |
| Earnings per Equity share (Basic) | 7.87 | 6.84 | 5.27 | 19.44 |
Consolidated Financial Results (Quarter Ended June 30, 2026)
The consolidated results reflect the performance of the Group, which includes subsidiaries and a joint venture.
| Particulars | 30th June 2026 (Unaudited) | 31st March 2026 (Audited) | 30th June 2025 (Unaudited) | 31st March 2026 (Audited) |
|---|---|---|---|---|
| Revenue from Operations (Net) | 53,579.69 | 58,264.40 | 38,619.09 | 181,944.25 |
| Total Income | 53,624.96 | 59,069.56 | 38,696.22 | 182,918.89 |
| Total Expenses | 44,259.49 | 51,452.99 | 32,434.88 | 160,147.11 |
| Profit before Tax (excluding exceptional items) | 9,365.47 | 7,616.56 | 6,261.34 | 22,771.78 |
| Net Profit for the period | 7,614.27 | 6,112.41 | 4,603.09 | 17,470.73 |
| Earnings per Equity share (Basic) | 8.40 | 6.74 | 5.08 | 19.27 |
AARTIPHARM Stock Price Movement
On Friday, shares of Aarti Pharmalabs Limited shed 1.16% of their value to settle at ₹685.85, following a decline of ₹8.05 from the previous close. The stock saw significant activity as it traded on a total volume of 179,726 shares during the session.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.